Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
暂无分享,去创建一个
T. Graeber | A. Ribas | Stephen Mok | G. McArthur | D. Knight | M. Smyth | R. Koya | Ashley A. Cass | H. Yagita | N. Haynes | Ming Li | S. Ngiow | Tiffany J. Parmenter | K. Kinross
[1] C. Blank,et al. Targeting BRAFV600E in an inducible murine model of melanoma. , 2012, The American journal of pathology.
[2] T. Graeber,et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. , 2012, Cancer research.
[3] Dennie T. Frederick,et al. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma , 2012, Clinical Cancer Research.
[4] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[5] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[6] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[7] M. Brown,et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.
[8] J. Sosman,et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. , 2012, Cancer discovery.
[9] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[10] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[11] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[12] J. Wilmott,et al. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.
[13] M. Smyth,et al. Prospects for TIM3-Targeted Antitumor Immunotherapy. , 2011, Cancer research.
[14] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[15] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[17] Jinghang Zhang,et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.
[18] K. Flaherty,et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Smyth,et al. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. , 2011, Cancer research.
[20] S. Loi,et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.
[21] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[22] B. Comin-Anduix,et al. The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations , 2010, Clinical Cancer Research.
[23] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[24] M. Herlyn,et al. PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas , 2010, Pigment cell & melanoma research.
[25] Marc Vidal,et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.
[26] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[27] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[28] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[29] K. Flaherty,et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.
[30] K. Pienta,et al. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.
[31] Paul S Mischel,et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032 , 2010, Journal of Translational Medicine.
[32] A. Möller,et al. IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis , 2010, Proceedings of the National Academy of Sciences.
[33] M. Smyth,et al. CD1d-Based Combination Therapy Eradicates Established Tumors in Mice1 , 2009, The Journal of Immunology.
[34] S. Rosenberg,et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.
[35] N. Ibrahim,et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice , 2009, Oncogene.
[36] A. Richmond,et al. The good and the bad of chemokines/chemokine receptors in melanoma , 2009, Pigment cell & melanoma research.
[37] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[38] I. Porfyridis,et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. , 2008, Journal of the National Cancer Institute.
[39] Antoni Ribas,et al. Targeted Therapies to Improve Tumor Immunotherapy , 2008, Clinical Cancer Research.
[40] S. Rosenberg,et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.
[41] S. Akira,et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis , 2008, Proceedings of the National Academy of Sciences.
[42] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[43] J. Xiong,et al. Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominanted cytokines and inhibits melanoma metastasis , 2007 .
[44] A. Mantovani,et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. , 2007, The Journal of investigative dermatology.
[45] M. Smyth,et al. Eradication of established tumors in mice by a combination antibody-based therapy , 2006, Nature Medicine.
[46] Christine E. Brown,et al. Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells1 , 2006, The Journal of Immunology.
[47] P. Gimotty,et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three‐dimensional organotypic culture is dependent on CCL2 and CCR4 , 2006, European journal of immunology.
[48] A. Hamann,et al. Homing to suppress: address codes for Treg migration. , 2005, Trends in immunology.
[49] M. Smyth,et al. Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.
[50] B. Rollins,et al. Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1–deficient Mice , 1998, The Journal of experimental medicine.
[51] A. Mantovani,et al. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. , 1991, Journal of immunology.
[52] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[53] M. Fujimoto,et al. Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. , 2012, The American journal of pathology.
[54] D. Heitjan,et al. CCL2 blockade augments cancer immunotherapy. , 2010, Cancer research.
[55] M. Smyth,et al. Chemokine-chemokine receptors in cancer immunotherapy. , 2009, Immunotherapy.
[56] A. Sica,et al. Tumor promotion by tumor-associated macrophages. , 2007, Advances in experimental medicine and biology.